COVID-19 research briefs by Essential Evidence Plus (EE+)

COVID-19 research briefs by Essential Evidence Plus (EE+)

As the COVID-19 pandemic continues to evolve, the Joule team is working closely with Dr. Mark Ebell, Editor-in-Chief of EE+ and the team at Wiley Publishing to share current research summaries with physicians.

POEMs* subscribers will receive COVID-19 related research briefs on most weekends and on select weekdays. You can view these updates below, subscribe to receive daily POEMS, refer to the POEMs archive (cma.ca login required) to comment on these summaries or collect CPD credits, or refer to the Essential Evidence Plus COVID-19 website.

Essential Evidence Plus (EE+) is making relevant COVID-19 information freely available, to help physicians caring for patients around the world. Topic updates on Coronavirus SARS-CoV2 infection (COVID-19) are being made as new information becomes available.

Clinical Question

Does COVID-19 increase the risk of thromboembolic events in high-risk patients?

Bottom line

Retrospective data suggests a high incidence of thrombotic events in hospitalized COVID-19 patients, particularly in patients with risk factors. 2c

Author(s)

Mark H. Ebell, MD, MS

Clinical Question

How effective are the different types of face masks for preventing the spread of COVID-19?

Bottom line

Based on laser testing, N95 masks transmitted less than 0.1% of respiratory droplets of COVID-19. 2c

Author(s)

Henry C. Barry, MD, MS

Clinical Question

Which measures are most effective to quickly contain an outbreak of SARS-CoV-2? How long do antibodies persist and can they be used to estimate infection fatality ratio?

Bottom line

China contains Beijing outbreak in one month. #56: Research in Iceland suggests that antibodies persist for 4 months after infection and infection fatality ratio is 0.3%, but much higher in older patients (4.4% if older than 70 years). 2c

Author(s)

Mark H. Ebell, MD, MS

Clinical Question

Which drugs and drug regimens are effective for treating COVID-19?

Bottom line

The BMJ systematic review supplies a summary of early data for drugs trialed for COVID-19 with plans to revisit the data frequently. Similar outcomes of remdesivir for 5 days versus 10 days versus usual care in patients with moderate COVID-19 pneumonia 1a

Author(s)

Henry C. Barry, MD, MS

Clinical Question

Can physical distancing reduce the transmission of COVID-19? Is colchicine a potential treatment option?

Bottom line

Physical distancing measures are effective in reducing COVID-19 transmission. Colchicine yielded small clinical improvements in a preliminary randomized trial. 2c

Author(s)

John Hickner, MD, MS

Clinical Question

What longer term symptoms follow hospitalization for COVID-19? Is a vaccine developed in China a possible solution?

Bottom line

Persistent fatigue, dyspnea, and other symptoms commonly follow hospitalization for COVID-19. Chinese researchers report a successful Phase 2 trial of a COVID-19 vaccine. 2c

Author(s)

Mark H. Ebell, MD, MS

Clinical Question

What is the progress on the development of a vaccine against SARS-CoV-2?

Bottom line

There is promising early data from the United States and the United Kingdom on new vaccines to prevent COVID-19. 3b

Author(s)

Henry C. Barry, MD, MS

 

 

*DisclaimerPOEMs stands for Patient-Oriented Evidence that Matters. POEMs is a publication of John Wiley and Sons, Inc. and distributed by Joule as a CMA Member service. All content is provided for information and education and not as a substitute for the advice of a physician. Joule assumes no responsibility or liability arising from any error or omission or from the use of any information contained herein.